Man Group plc Makes New $293,000 Investment in Certara, Inc. (NASDAQ:CERT)

Man Group plc bought a new position in Certara, Inc. (NASDAQ:CERT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 27,520 shares of the company's stock, valued at approximately $293,000.

A number of other large investors have also added to or reduced their stakes in CERT. Venturi Wealth Management LLC lifted its stake in shares of Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after buying an additional 2,509 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. purchased a new position in shares of Certara during the 4th quarter valued at $47,000. Blue Trust Inc. lifted its stake in shares of Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after buying an additional 822 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its stake in shares of Certara by 204.7% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock valued at $58,000 after buying an additional 3,656 shares in the last quarter. Institutional investors own 73.96% of the company's stock.

Certara Stock Performance

Shares of NASDAQ CERT traded up $0.08 during midday trading on Thursday, reaching $11.40. The company had a trading volume of 876,077 shares, compared to its average volume of 1,336,482. The stock has a market cap of $1.85 billion, a P/E ratio of -57.00, a P/E/G ratio of 9.29 and a beta of 1.57. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $17.76. The business's 50-day simple moving average is $11.83 and its 200 day simple moving average is $11.77. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm's revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the business earned $0.10 earnings per share. On average, analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CERT has been the topic of several research analyst reports. TD Cowen initiated coverage on shares of Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 price target on the stock. Robert W. Baird boosted their price target on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Stephens reiterated an "overweight" rating and issued a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. JMP Securities reiterated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Finally, KeyCorp boosted their price target on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $15.67.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.